| Description | Contezolid acefosamil (MRX-4), an orally active prodrug, is metabolized into Contezolid (MRX-I), an oxazolidinone derivative with potent in vitro efficacy against multidrug-resistant Gram-positive bacteria, including MRSA. |
| Synonyms | MRX-4, Contezolid acefosamil |
| molecular weight | 530.353 |
| Molecular formula | C20H18F3N4O8P |
| CAS | 1807497-11-5 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Matteo Bassetti, et al. Innovative therapies for acute bacterial skin and skin-structure infections (ABSSSI) caused by methicillin-resistant Staphylococcus aureus: advances in phase I and II trials. Expert Opin Investig Drugs. 2020 May;29(5):495-506. |